BrainChild Bio

At the heart of BrainChild Bio is a mission deeply rooted in a 'kids-first' philosophy, challenging the conventional drug development paradigm that often leaves pediatric patients as an afterthought. Spun out of Seattle Children's Hospital, the company is driven by a culture of relentless innovation and compassion, dedicated to harnessing the power of CAR T-cell technology to treat central nervous system (CNS) tumors. The team is united by a singular purpose: to bring the best scientific ideas forward and push the boundaries of discovery to serve children with cancer who have historically been deprioritized.

BrainChild Bio's approach is not just about developing therapies; it's about rewriting the narrative for families facing incurable diagnoses like diffuse intrinsic pontine glioma (DIPG). By prioritizing pediatric indications with plans to expand to adult brain tumors, the company embodies a commitment to equity and urgency in medical advancement. Their work leverages over a decade of translational research, weaving together synthetic technologies to create safe, effective, and transformational treatments. This dedication to 'cracking the code' of CNS tumors reflects a team culture that values expertise, creativity, and an unwavering dedication to giving children the chance to grow and thrive.